OTEZLA DELIVERS RAPID AND SUSTAINED RELIEF FROM PRURITUS1*
Sustained reductions in pruritus up to 32 weeks1,a
aESTEEM 1 study. Data as observed from patients in the full analysis set. Results were consistent between ESTEEM 1 and ESTEEM 2.
- Among patients treated with OTEZLA 30 mg BID, improvements in pruritus VAS scores correlated with DLQI scores (rs = 0.55 [week 16]; rs ≥0.51 [week 32]; P < 0.001)1
OTEZLA significantly reduces pruritus severity as early as week 21
*Pruritus was measured on a 100-mm VAS. Baseline values: Placebo, 65.0 mm; OTEZLA 30 mg BID, 66.1 mm.
BID, twice daily; BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.
- Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514-520.